Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.

BMC medical genomics - 19 Jan 2024

Guo Liantao, Cheng Hong, Liu Jianhua, Shao Weikang, Luo Lan, Zheng Weijie, Sun Shengrong, Kong Deguang, Chen Chuang

Abstract excerpt

BACKGROUND: Breast cancer is the second leading cause of cancer-related death in women, and drug resistance during treatment is a major challenge. However, the mechanisms underlying drug resistance are not fully understood. Here we applied whole-exome sequencing (WES) to clarify resistant rules to Herceptin and tyrosine kinase inhibitors (TKIs). METHODS: There are 12 HER2+ breast cancer patients who were done...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apolipoproteins B
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Exome Sequencing

Share to Mutation

Share to Neoplasm Recurrence, Local

Share to Trastuzumab

Source

Open in PubMed Open full text

Identifiers

PMID: 38243282
DOI: 10.1186/s12920-023-01762-x
PMCID: PMC10799408

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Based on whole-exome sequencing to explore the rule of Herceptin and TKI resistance in breast cancer patients.PMID 38243282Read ↗

Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.Semantic proximity Read ↗

Genomic mechanisms of resistance to tyrosine kinase inhibitors in HER2 amplified breast cancerSemantic proximity Read ↗

The Underlying Mechanisms and Emerging Strategies to Overcome Resistance in Breast CancerSemantic proximity Read ↗

Concurrent Mutations Associated With Trastuzumab-resistance Revealed by Single Cell SequencingSemantic proximity Read ↗

Comprehensive molecular profiling of Taiwanese breast cancers revealed potential therapeutic targets: prevalence of actionable mutations among 380 targeted sequencing analysesSemantic proximity Read ↗

Whole exome sequencing for identification of specific gene mutations in an Indian cohort of triple- negative breast cancer patientsSemantic proximity Read ↗

Genetic Influences in Breast Cancer Drug ResistanceSemantic proximity Read ↗

Concurrent mutations associated with trastuzumab-resistance revealed by single cell sequencing.Semantic proximity Read ↗

Discovery of Proteins Responsible for Resistance to Three Chemotherapy Drugs in Breast Cancer Cells Using Proteomics and Bioinformatics AnalysisSemantic proximity Read ↗

Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumoursSemantic proximity Read ↗

Clonal selection supported by single cell Dna sequencing reveals hormonal adaptation and resistance in locally advanced breast cancer During Neoadjuvant Aromatase InhibitionSemantic proximity Read ↗

Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor–Positive Breast CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.